TABLE 4.
Haemostasis management in WGH for the most recent births during the study period
| In preparation for/during delivery | Within 6 weeks postpartum | |||||
|---|---|---|---|---|---|---|
| Overall (n = 7) a | FVIII deficiency (n = 6) | FIX deficiency (n = 1) | Overall (n = 7) a | FVIII deficiency (n = 6) | FIX deficiency (n = 1) | |
| Medication, n | ||||||
| Yes | 4 | 3 | 1 | 5 | 4 | 1 |
| No | 2 | 2 | 0 | 2 | 2 | 0 |
| Unknown | 1 | 1 | 0 | 0 | 0 | 0 |
| Type of medication, n (%) | ||||||
| Antifibrinolytic | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (28.6) | 1 (16.7) | 1 (100.0) |
| FVIII concentrate | 3 (42.9) | 3 (50.0) | NA | 2 (28.6) | 2 (33.3) | NA |
| FIX concentrate | 1 (14.3) | NA | 1 (100.0) | 1 (14.3) | NA | 1 (100.0) |
| Other | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (14.3) | 1 (16.7) | 0 (0.0) |
| Blood transfusion, n (%) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (28.6) | 1 (16.7) | 1 (100.0) |
| Iron supplementation, n (%) | NA | NA | NA | 3 (42.9) | 2 (33.3) | 1 (100.0) |
| Clinical outcomes, n (%) b | ||||||
| Bleeding stopped | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (20.0) | 1 (25.0) | 0 (0.0) |
| Bleeding with sufficient control c | 3 (75.0) | 3 (100.0) | 0 (0.0) | 2 (40.0) | 1 (25.0) | 1 (100.0) |
| Bleeding with insufficient control d | 1 (25.0) | 0 (0.0) | 1 (100.0) | 2 (40.0) | 2 (50.0) | 0 (0.0) |
Abbreviations: FIX, factor IX; FVIII, factor VIII; NA, not applicable; WGH, women and girls with haemophilia.
a
Patients for whom data on the most recent delivery were available. Patients may have received multiple treatments.
b
Patients in the subset who received medical haemostasis management in preparation for/or during the most recent delivery and/or within 6 weeks postpartum.
c
Bleeding as normally expected for a normal pregnancy was considered bleeding with sufficient control.
d
Bleeding control worse than normally expected for normal pregnancy was considered bleeding with insufficient control.